Immunization methods are provided. The methods typically include administering the subject an effective amount of an antigen and adjuvant to induce an immune response against an antigen, the method including two or more of (i) slow prime delivery of antigen and/or adjuvant, a (ii) temporally delayed 2nd immunization, and (iii) a robust adjuvant. Element (i) can be or include temporally extended exposure of antigen, adjuvant, or preferably the combination thereof, such as one or more of repeated administrations, infusion optionally by osmotic pump and escalating dosing. Element (ii) can include administering one or more boost doses of antigen and/or adjuvant, for example between 11 and 35 weeks after the start of the prime administration. A preferred robust adjuvant (iii) is one including non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin.

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.

A method of preparing a composition comprising one or more antigens adsorbed to an amino acid wherein said method comprises: (i) mixing a solution of one or more antigens with a solution of the amino acid in an aqueous acid whilst neutralizing the mixture of solutions, thereby forming an adsorbate comprising the one or more antigens and the amino acid; (ii) separating the adsorbate into a desired buffer by cross-flow filtration thereby forming said composition; and (iii) recovering said composition; wherein steps (i) to (iii) are performed in a sterile environment and within a closed system.

Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.

Provided are multivalent pneumococcal conjugate compositions comprising 22-27 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of Streptococcus pneumoniae, wherein the Streptococcus pneumoniae CA serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10 A, 11 A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23 A, 23B, 23F, 24F, 33F, and 35B. Also provided are methods of producing the multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject. Also provided are immunogenic compositions comprising at least one polysaccharide-protein conjugate wherein the polysaccharide is a capsular polysaccharide from CN Streptococcus pneumoniae serotype 15A, 15C, 23 A, 23B, 24F, and/or 35B and methods of preparing the same.

A carrier system that includes a nanocarrier and a peptide non-covalently associated with the nanocarrier. The peptide contains an adaptor peptide sequence fused to the N-terminus of a target peptide, the adaptor peptide sequence being designed to facilitate the association to the nanocarrier. Also disclosed is a method for improving the immunogenicity of a peptide antigen by fusing it to an adaptor peptide sequence to form an immunizing peptide and contacting the immunizing peptide with a compatible nanocarrier. Further, a method is provided for treating a condition by immunization with a target peptide that has been fused to an adaptor peptide sequence and thereby associated with a nanocarrier. The method induces an immune response against the target peptide for treating cancer, viral infection, bacterial infection, parasitic infection, autoimmunity, or undesired immune responses to a biologies treatment.

A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.

Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.